Castle Biosciences

350 articles about Castle Biosciences

• Castle Biosciences Announces Publication Demonstrating Dermatologists Are Increasingly Integrating DecisionDx-Melanoma Into Melanoma Clinical Management Decisions

  3/25/2021

  Cross-Sectional Study of 589 U.S. Dermatological Clinicians Demonstrating Clinical Utility Was Recently Published in SKIN: The Journal of Cutaneous Medicine

• Castle Biosciences Launches DecisionDx-Melanoma Integrated Test Result Utilizing Artificial Intelligence to Predict Individualized Risk

  3/8/2021

  Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced that DecisionDx®-Melanoma, Castle’s prognostic gene expression profile test for cutaneous melanoma, now utilizes an Integrated Test Result (ITR)

• Castle Biosciences to Present at Upcoming Investor Conferences - Feb 08, 2021

  2/8/2021

  Castle Biosciences, Inc., a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, announced that Derek Maetzold, president and chief executive officer, is scheduled to present a company overview at the following upcoming investor conferences:

• Castle Biosciences Presents New Data on the Validity and Accuracy of DecisionDx-Melanoma in Patients With T1 Cutaneous Melanoma Tumors at the 19th Annual South Beach Symposium

  2/4/2021

  Castle Biosciences Presents New Data on the Validity and Accuracy of DecisionDx-Melanoma in Patients With T1 Cutaneous Melanoma Tumors at the 19 th Annual South Beach Symposium Additional Virtual Posters Highlight Data on DecisionDx® DiffDx™-Melanoma and DecisionDx®-SCC

• Castle Biosciences to Present Data on DecisionDx®-Melanoma, DecisionDx® DiffDx™-Melanoma at 18th Annual Winter Clinical Dermatology Conference

  1/20/2021

  Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced poster presentations with data on two of its skin cancer gene expression profile tests at the 18th Annual Winter Clinical Dermatology Conference, taking place virtually from Jan. 15 – 24, 2021.

• Castle Biosciences Announces Preliminary Fourth Quarter and Full-Year 2020 Results

  1/13/2021

  Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced certain unaudited preliminary performance results for the fourth quarter and full-year 2020.

• Castle Biosciences Announces Early Repayment of Debt

  12/22/2020

  Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced it prepaid in full its outstanding term loan facility to further improve its balance sheet.

• Castle Biosciences Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

  12/18/2020

  Castle Biosciences, Inc., announced the closing of its previously announced underwritten public offering of 4,600,000 shares of its common stock, including the exercise in full by the underwriters of their option to purchase an additional 600,000 shares, at a public offering price of $58.00 per share.

• Castle Biosciences Announces Pricing of $232 Million Public Offering of Common Stock

  12/16/2020

  Castle Biosciences, Inc. (Nasdaq: CSTL), announced today the pricing of its underwritten public offering of 4,000,000 shares of its common stock at a price to the public of $58.00 per share.

• Castle Biosciences Announced Commencement of Proposed Public Offering of Common Stock

  12/14/2020

  Castle Biosciences, Inc. (Nasdaq: CSTL), announced today that it has commenced a proposed underwritten public offering, subject to market and other conditions, to issue and sell $125,000,000 of shares of its common stock. In connection with the offering, Castle expects to grant the underwriters a 30-day option to purchase up to an additional $18,750,000 of shares of common stock. All of the shares in the proposed offe

• Castle Biosciences Announces Publication of Peer-Reviewed Publication Demonstrating the Clinical Impact of DecisionDx®-Melanoma

  12/4/2020

  Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced the publication of a clinical use study demonstrating that management decisions for patients diagnosed with American Joint Committee on Cancer (AJCC) 7th edition stage I – III melanoma were impacted by the use of DecisionDx-Melanoma,

• Castle Biosciences to Participate in Piper Sandler 32nd Annual Virtual Healthcare Conference

  11/23/2020

  Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced that management will participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference, December 1-3, 2020.

• Castle Biosciences Announces Publication of Clinical Validation and Utility Data for DecisionDx® DiffDx™-Melanoma for Suspicious Pigmented Lesions

  11/17/2020

  Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced the publication of two studies in SKIN: The Journal of Cutaneous Medicine , which demonstrated that DecisionDx® DiffDx™-Melanoma adds significant diagnosti

• Castle Biosciences Presents Data on DecisionDx®-Melanoma and DecisionDx® DiffDx™-Melanoma Tests at American Society of Dermatopathology (ASDP) 57th Virtual Annual Meeting

  11/12/2020

  Castle Biosciences Presents Data on DecisionDx ® -Melanoma and DecisionDx ® DiffDx™-Melanoma Tests at American Society of Dermatopathology (ASDP) 57 th Virtual Annual Meeting FRIENDSWOOD, Texas--( BUSINESS WIRE )-- Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced the presentation of data on two of its skin cancer gene expression p

• Castle Biosciences Announces Third Quarter 2020 Results

  11/9/2020

  Q3 2020 revenues of $15.2 million, Q3 2020 YTD revenues of $45.4 million DecisionDx-Melanoma report volume returned to quarterly year-over-year increase Q3 2020 gross margin of 84% Recently received final expanded positive Medicare coverage for DecisionDx-Melanoma

• Castle Biosciences to Present at the Canaccord Genuity 2020 Virtual MedTech & Diagnostics Forum

  11/5/2020

  Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced that Derek Maetzold, president and chief executive officer, is scheduled to present a company overview at the Canaccord Genuity 2020 Virtual MedTech & Diagnostics Forum on Nov. 19, 2020, at 9:30 a.m. Eastern time. A live audio webcast of

• Castle Biosciences Announces Commercial Launch of DecisionDx DiffDx-Melanoma

  11/2/2020

  Diagnostic gene expression profile test for suspicious pigmented lesions now commercially available in the U.S.

• Castle Biosciences to Present Data at the American Society of Dermatopathology (ASDP) 57th Virtual Annual Meeting

  10/29/2020

  Castle Biosciences to Present Data at the American Society of Dermatopathology (ASDP) 57 th Virtual Annual Meeting Presentations to highlight two of Castle’s skin cancer gene expression profile tests

• Castle Biosciences to Release Third Quarter 2020 Financial Results and Host Conference Call on Monday, November 9, 2020

  10/26/2020

  Castle Biosciences, Inc., a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, announced that it will release its financial results for the third quarter ended Sept. 30, 2020, after the close of market on Monday, Nov. 9, 2020.

• Castle Biosciences to Hold Webcast for Investors Highlighting Commercial Launch of ConfirmDx®-Melanoma

  10/21/2020

  ConfirmDx-Melanoma is Castle’s gene expression profile test for suspicious pigmented lesions